Arca
Skip to content
Tools
Tools

Hyperuricemia

Drug research and approvals for hyperuricemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 19, 2026, 26 studies of hyperuricemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 3 approved and 4 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 26
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 3
  • EU medicines: 3

Recruiting now

Newest posted first, of 26 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 3

Phase 3 1

Phase 2 7

Phase 1 or earlier 2

How its trials ended

186 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 34 whose ending is known, 62% met their primary endpoint, 12% missed it and 26% stopped early.

  • Completed, result not reported8646%
  • Status unknown3921%
  • Ongoing2715%
  • Met its primary endpoint2111%
  • Stopped: enrollment or feasibility53%
  • Missed its primary endpoint42%
  • Stopped: other or unclear21%
  • Stopped: sponsor or business decision11%
  • Stopped: funding11%

FDA orphan designations

Approved first, then open designations, newest first
Jul 7, 2022KrystexxaTreatment of chronic gout in adult patients refractory to conventional therapyHorizon Therapeutics Ireland DACApproved
Sep 14, 2010KrystexxaTreatment of chronic gout in adult patients refractory to conventional treatmentHorizon Therapeutics Ireland DACApproved
Jul 12, 2002ElitekInitial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving…Sanofi-Synthelabo ResearchApproved
Jun 6, 2005Polyethylene glycol-modified uricaseTreatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicatedSwedish Orphan Biovitrum ABDesignated
Oct 11, 2000Recombinant urate oxidaseProphylaxis of chemotherapy-induced hyperuricemia.Sanofi-Synthelabo ResearchDesignated
Sep 14, 1999Polyethylene glycol-modified uricaseProphylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.Swedish Orphan Biovitrum ABDesignated
Nov 9, 1998OxypurinolTreatment of hyperuricemia in patients intolerant to allopurinol.Cardiome Pharma Corp.Designated

Medicines authorised in the EU

Newest first
Mar 28, 2019Febuxostat KrkaFebuxostat · genericKRKA tovarna zdravil d.d. Novo mestoEMA ↗
Jun 15, 2017Febuxostat Viatris (previously Febuxostat Mylan)Febuxostat · genericViatris LimitedEMA ↗
Feb 23, 2001FasturtecRasburicaseSanofi Winthrop IndustrieEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.